Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Giant Cell Arteritis
NCT03192969Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Primary completion
- Jun 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of abatacept in giant cell arteritis (GCA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Patients in sustained remission at 40 weeks. Planned start Jul 2017; status: withdrawn.
02
Drugs
abatacept
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03192969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192969.